NCT06810778View on ClinicalTrials.gov

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 2, 2025

Primary Completion Date

June 1, 2030

Study Completion Date

June 1, 2031

Conditions
T-cell-prolymphocytic LeukemiaCutaneous T-Cell Lymphoma Refractory
Interventions
DRUG

Duvelisib

15 and 25 mg BID

DRUG

Venetoclax

200, 400, and 800 mg QD

Trial Locations (1)

90095-1406

RECRUITING

David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER

NCT06810778 - Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Biotech Hunter | Biotech Hunter